Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 20/20 | 0.70 |
| ▸ | GABRG2 | P18507 | 20/20 | 0.70 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.70 |
| ▸ | GABRA3 | P34903 | 17/20 | 0.70 |
| ▸ | GABRA5 | P31644 | 14/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30139355 | 1.00 | GABRA1 (0.70) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659281 | 0.93 | GABRA1 (0.81) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659917 | 0.90 | GABRA1 (0.86) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659569 | 0.88 | GABRA1 (0.66) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659759 | 0.88 | GABRA1 (0.61) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659859 | 0.87 | GABRA1 (0.81) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659881 | 0.87 | GABRA1 (0.61) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2658720 | 0.86 | GABRA1 (0.61) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659472 | 0.86 | GABRA1 (0.79) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2658463 | 0.84 | GABRA1 (0.68) | GABRA1GABRG2GABRB3GABRA3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-21 | — | — | US | claimed |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-10 | — | — | US | claimed |
| US-20200179374-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-11 | — | — | US | claimed |
| EP-3468545-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | President and Fellows of Harvard College (US) | 2019-04-17 | — | — | EP | claimed |
| WO-2017214442-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-12-14 | — | — | WO | claimed |
| EP-1511747-B1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-04-12 | — | — | EP | claimed |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2005-07-28 | — | — | US | claimed |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200179374-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3468545-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | President and Fellows of Harvard College (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017214442-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-1511747-B1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-04-12 | — | — | EP | disclosed |
| EP-1511747-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099816-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | MECP2, GABBR1, GABBR2 | GABRA1 11/4885GABRG2 12/4885GABRB3 6/4885 |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA5 | GABRA1 5/4885GABRG2 15/4885GABRB3 6/4885 |
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | MECP2, GABBR1, GABBR2 | GABRA1 11/4885GABRG2 12/4885GABRB3 6/4885 |
| US-20200179374-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MECP2, GABBR1, GABBR2 | GABRA1 11/4885GABRG2 12/4885GABRB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.